Eli Lilly and Company (NYSE:LLY) Stock Unloaded Sen. Ron Wyden

Senator Ron Wyden (D-Oregon) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had sold between $50,001 and $100,000 in Eli Lilly and Company stock on February 10th.

Senator Ron Wyden also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of iRobot (NASDAQ:IRBT) on 2/6/2025.
• Sold $1,001 – $15,000 in shares of Solventum (NYSE:SOLV) on 2/6/2025.
• Purchased $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 1/22/2025.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $874.12 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market capitalization of $829.82 billion, a price-to-earnings ratio of 74.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.42. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The stock has a 50-day simple moving average of $801.33 and a 200 day simple moving average of $846.75.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Eli Lilly and Company announced that its Board of Directors has authorized a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages recently weighed in on LLY. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company’s stock worth $57,320,226,000 after purchasing an additional 475,530 shares during the period. Geode Capital Management LLC lifted its position in Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock worth $13,389,651,000 after purchasing an additional 291,875 shares during the period. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the period. International Assets Investment Management LLC lifted its position in Eli Lilly and Company by 87,091.7% in the third quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company’s stock worth $11,041,631,000 after purchasing an additional 12,448,888 shares during the period. Finally, Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter worth approximately $8,407,908,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Senator Wyden

Ron Wyden (Democratic Party) is a member of the U.S. Senate from Oregon. He assumed office on January 30, 1996. His current term ends on January 3, 2029. Wyden (Democratic Party, Independent Party) ran for re-election to the U.S. Senate to represent Oregon. He won in the general election on November 8, 2022. He advanced from the Democratic primary on May 17, 2022. In 2018, the Town Hall Project, which described itself as “a citizen powered, grassroots effort that empowers constituents across the country to have face-to-face conversations with their elected representatives,” named Wyden town hall MVP for the second year in a row. According to OregonLive, Wyden held over 900 town hall meetings between 1996 and 2018. Wyden previously served in the U.S. House of Representatives, representing Oregon’s 3rd Congressional District from 1981 to 1996. As of a 2014 analysis of multiple outside rankings, Wyden is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.